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Abstract
Background: The use of newer azoles as prophylaxis in hematological patients undergoing stem cell
transplantation or immunosuppressive chemotherapy has been shown to decrease the risk of developing invasive
fungal disease (IFD). However, the cost-effectiveness of such a strategy is dependent on the local epidemiology of
IFD. We conducted an audit of hematological patients with IFD in our institution in order to derive the prevalence
and types of IFD that occur locally.
Findings: We conducted a retrospective chart review of all hematological patients who developed possible,
probable or definite IFD according to EORTC/MSG criteria in the period from Oct 2007 to Apr 2010. The prevalence
of IFD was determined via correlation with institutional database records of all hematological patients treated at
our institution over the same time period.
There were 39 cases of IFD diagnosed during the study period, with 8 (20.5%) possible, 19 (48.7%) probable and 12
(30.8%) definite cases of IFD. Aspergillus spp. accounted for 83.9% of all probable and definite infections. There was
1 case each of Rhinocladelia spp., Coprinopsis cinerea, Exserohilum spp. sinusitis and Rhizopus spp. sinusitis. IFD
occurred in 12 of 124 (9.7%) AML and 4 of 103 (3.9%) ALL patients treated at our institution respectively. There
were 10 (16.1%) infections among 62 allogeneic HSCT recipients, six of whom were having concurrent graft-versus-
host disease (GVHD). Five other cases occurred after allogeneic HSCT failure, following salvage chemotherapy for
disease relapse. The prevalence of IFD during induction chemotherapy was 8.9% (11 of 124 cases) for AML and
1.0% (1 of 103 cases) for ALL. Fluconazole prophylaxis had been provided for 28 out of the 39 (71.8%) cases, while
4 (10.3%) were on itraconazole prophylaxis. The in-hospital mortality was 28.2% (11 of 39 cases), of which 5 (12.8%)
deaths were attributed to IFD.
Conclusions: The burden of IFD is high in our institution, especially in allogeneic HSCT recipients and patients on
induction chemotherapy for AML. A prophylactic strategy directed against invasive mould infections for local high-
risk patients may be considered as the comparative costs of treatment, prolonged hospitalisation and subsequent
delayed chemotherapy favours such an approach.
Background
Antifungal prophylaxis is recommended for patients
undergoing induction chemotherapy for acute myeloid
leukemia (AML) and patients with allogeneic hemato-
poietic stem cell transplantation (HSCT) undergoing
treatment for chronic extensive graft-versus-host disease
(GVHD) [1,2]. It may also benefit other patient
subpopulations at high risk of invasive fungal disease
(IFD) - those with prolonged neutropenia after stem cell
transplantation using bone marrow or cord blood
sources, or those with impaired cell-mediated immunity
secondary to therapeutic agents such as alemtuzumab
[1]. Several key factors should be considered before
deciding on whether to use prophylaxis and which agent
to use. These include: the effectiveness against the types
of fungi to be covered, institutional fungal epidemiology
in the select group of patients with hematological
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city profile and drug interactions of the antifungal agent.
With the advent of new antifungals being used for
prophylaxis for patients with hematological malignan-
cies, fungal infection-related mortality has decreased [3].
However, this has also resulted in a shift in the epide-
miology of invasive mycoses, with an increase in the
prevalence of invasive mold infections among HSCT
recipients and patients with hematological malignancies
against a backdrop of a greater decline in prevalence of
invasive candidiasis [4,5].
Currently at our hospital, fluconazole is the antifungal
prophylactic agent used in patients with hematological
malignancies receiving chemotherapy and allogeneic or
autologous HSCT. Posaconazole, an extended-spectrum
triazole, is active against most pathogenic yeasts and
moulds [6], and has been approved for use as antifungal
prophylaxis in the subgroup of allogeneic HSCT recipients
with GVHD as well as profoundly neutropenic patients
with AML and/or myelodysplastic syndromes (MDS) [6].
We performed an audit of hematology patients with
IFD at our hospital - a 995-bed university hospital in
Singapore with a large hematology and stem cell trans-
plantation center. Our rationale for embarking on this
study is to derive the epidemiology of IFD locally so as
t od e t e r m i n ei ft h e r ei sar o l ef o ras w i t c ht op o s a c o n a -
zole prophylaxis in the immediate future.
Methods
A retrospective chart review was performed on all
hematology patients diagnosed with IFD that were hos-
pitalized between 1 October 2007 to 30 April 2010, out-
lining their outcomes and the prevalence of IFD
according to the underlying hematological disease. All
hematology patients with IFD in our institute are cap-
tured on a database at the point of diagnosis. In general,
diagnostic workup for IFD was directed by patient
symptoms, with the exception of persistent (>5 days)
febrile neutropenia, where a computed tomography
(CT) scan of the thorax was performed routinely. Serum
galactomannan was performed weekly for HSCT recipi-
ents, while bronchoalveolar lavage (BAL) with galacto-
mannan testing of BAL fluid was performed routinely
for patients with CT thorax findings suggestive of fungal
infection [7] but negative serum galactomannan. Tissue
biopsies were performed where possible (platelet count
>50,000 cells/μL).
The number of patients diagnosed with AML and
acute lymphocytic leukemia (ALL) in the study period
was derived from the hematology cytogenetics labora-
tory registry, while the number of allogeneic HSCT
patients was obtained from the center’sH S C Tr e g i s t r y .
IFD cases were classified as possible, probable or defi-
nite IFD according to the 2007 European Organization
for Research and Treatment of Cancer Invasive Fungal
Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) criteria, with physicians routinely
screening through all CT pulmonary images if these had
been performed looking for specific signs of fungal
infection [7]. We followed EORTC/MSG recommenda-
tions for serum galactomannan optical density (OD)
cutoffs, whereas the BAL galactomannan OD cutoff was
>1.0 [8].
Variables collected included demographic and clinical
data as well as outcomes - in-hospital mortality and
IFD-related mortality. The latter was determined follow-
ing chart review by an infectious diseases specialist, and
was based on the presence of ongoing progressive fungal
disease with no other apparent cause of death present.
This study is a subset of a larger febrile neutropenia
program evaluation that was approved by the institu-
tional ethics review committee (National Healthcare
Group Domain Specific Review Board E/09/340).
Results
During the study period, 103 and 124 patients were
diagnosed and provided induction +/- consolidation
therapy for ALL and AML respectively, while 135
patients received HSCT (62 allogeneic, including 6 cord
blood transplants, and 73 autologous transplants) for a
variety of haematological disorders. Locally, fluconazole
capsules or less frequently itraconazole solution are rou-
tinely provided as antifungal prophylaxis to patients
with leukemia receiving chemotherapy and HSCT
recipients.
There were 39 cases of IFD diagnosed during this per-
iod, of which 8 (20.5%) were possible, 19 (48.7%) were
probable and 12 (30.8%) were definite IFD according to
EORTC/MSG criteria [7], with all definite IFD cases
confirmed via histopathological detection of tissue-
invasive fungi in biopsy specimens. 28 (71.7%) patients
were on fluconazole, 4 (10.3%) were on itraconazole
prophylaxis while the remainder received no antifungal
prophylaxis. Demographic and clinical characteristics of
these patients are shown in Table 1. The majority were
male, and Aspergillus spp. accounted for 83.9% of all
probable and definite infections. There was 1 case each
of Rhinocladelia spp. and Coprinopsis cinerea pulmonary
infection, 1 case of Exserohilum spp. pulmonary infec-
tion and sinusitis, and 1 case of Rhizopus spp. sinusitis.
The majority of cases of aspergillosis (96.5%) were
identified by positive galactomannan testing from serum
and/or BAL fluid. Fungal cultures from infected tissue
or BAL samples were positive only in 17.9% of cases.
Rhinocladelia spp. and Coprinopsis cinerea were identi-
fied by internal transcribed spacer (ITS) sequencing of
infected lung tissue [9].
Lee et al. BMC Research Notes 2011, 4:42
http://www.biomedcentral.com/1756-0500/4/42
Page 2 of 4Eleven (28.2%) patients with IFD died during their
hospitalization, with 5 (12.8%) deaths attributed to IFD.
There was only non-aspergillosis mortality, who devel-
oped rapidly progressing mucormycosis involving eth-
moid, maxillary, frontal and sphenoid sinuses as well as
the left cavernous sinus. Extensive debridement and
high-dose (10 mg/kg body weight) liposomal amphoteri-
cin B failed to control the infection and she died within
one week of diagnosis. Intra-operative tissue specimens
grew Rhizopus spp., while histology showed extensive
disease - broad hyphal fungal fragments present in the
blood vessels of the left inferior turbinate, within the
lumina and invading the vessel walls and surrounding
connective tissue stroma.
The prevalence of IFD in AML and ALL patients dur-
ing induction chemotherapy was 8.9% (11 of 124 cases)
and 1.0% (1 of 103 cases) respectively. The prevalence of
IFD in allogeneic HSCT recipients was 16.1% (10 of 62
patients), occurring during initial neutropenia or GVHD.
Discussion
Our audit showed that the prevalence of and mortality
related to IFD is high in our institution, and comparable
to previously published figures [4,5,10-13]. All cases of
probable and definite IFD were caused by molds, and
the paucity of invasive candidiasis in our patients can be
attributed to the use of fluconazole or itraconazole as
antifungal prophylaxis in hematological patients on che-
motherapy or HSCT recipients. It is plausible that sev-
eral possible IFD cases as defined by the EORTC/MSG
criteria did not actually have fungal infection. However,
it is not possible to differentiate these cases further
given the current limitations of fungal diagnostics. The
proportion of possible IFD relative to probable/definite
IFD has decreased over time with more frequent use of
BAL galactomannan testing [8].
Switching to posaconazole prophylaxis for at-risk
patients may result in a significant reduction of IFD at
our institution. Recent landmark trials have shown a
relative risk reduction for IFD of 0.73 and 0.41 respec-
tively during neutropenia and GVHD compared to flu-
conazole [10,11], with a number need to treat (NNT) of
16 and 27 respectively to prevent 1 fungal infection in
each group [10]. To prevent 1 fungal infection-related
death, the NNT was 27 and 33 for hematology patients
with neutropenia and allogeneic HSCT recipients with
GVHD respectively [14]. It is reasonable to assume that
similar results can be expected locally, given comparable
fungal epidemiology. However, our results also suggest
that providing posaconazole for high-risk patients such
as allogeneic HSCT recipients and AML patients on
induction chemotherapy will cover just over 56% of
potential future patients with IFD (assuming distribution
of IFD among future local hematology patients remains
constant), resulting in a reduction of approximately 42%
of our current prevalence of IFD given expected success
rates of posaconazole prophylaxis of 75%. These figures,
while significant, suggest that more needs to be done to
identify individual patients who are at risk for IFD.
The overall additional estimated cost of treating an IFD
at our institution is approximately USD8,600.00 (data not
shown), notwithstanding other adverse events such as a
delay in chemotherapy and longer hospitalization. The
current cost of posaconazole prophylaxis for a month is
approximately USD2,300.00. Although several studies
have shown that posaconazole prophylaxis is potentially
cost-effective when compared to fluconazole [15-17],
these are aggregate population-based results. The burden
of payment for antifungal prophylaxis rests on the
patients in our local setting as the cost of these drugs is
borne directly by the patient or private insurance. Posa-
c o n a z o l ep r o p h y l a x i so na ni n d ividual level in Singapore
m a yb ev i e w e da sb e i n gm o r eo fah e d g eo ri n s u r a n c e ,
and this may be a deterrent for those high-risk patients
who lack the necessary funds to pay for the drug.
This study had several limitations. Firstly, this was a ret-
rospective chart review and it is a plausible that even with
the existence of database, not all cases of IFD were diag-
nosed. Secondly, there were no autopsies performed on
Table 1 Demographic and clinical characteristics of
hematology patients with invasive fungal disease
Median age, years (range) 43 (17 - 88)
Male gender (%) 25 (64.1)
Hematological diagnosis:
AML (% AML with IFD in study period) 12 (9.7)
ALL (% ALL with IFD in study period) 4 (3.8)
Autologous transplants (% autologous HSCT recipients
with IFD)
1 (1.4)
Allogenic transplants (% allogeneic HSCT recipients
with IFD)
10 (16.1)
- Neutropenia post-transplantation (% allogeneic
HSCT recipients with IFD occurring during
neutropenia)
4 (6.5)
- GVHD (% allogeneic HSCT recipients with IFD
occurring during GVHD)
6 (9.7)
Relapsed leukemia on salvage chemotherapy
post-transplantation
5
Others* 7
Location of IFD:
Sinus (%) 5 (12.8)
Pulmonary (%) 34 (87.2)
Median serum galactomannan (range) for:
- All IFD cases (n = 41) 0.3 (0.1–4.3)
- All probable/definite aspergillosis cases (n = 26) 0.6 (0.1–4.3)
*Others include 2 cases with MDS, 2 cases with aplastic anemia, and one case
each of chronic myelomonocytic leukemia, angioimmunoblastic T-cell
lymphoma, and hemophagocytic lymphohistiocytosis secondary to T-cell
lymphoma.
Lee et al. BMC Research Notes 2011, 4:42
http://www.biomedcentral.com/1756-0500/4/42
Page 3 of 4the patients who had died. This may have led to an under-
estimation of the mortality that could be attributed to IFD.
Conclusions
In conclusion, our audit revealed that the prevalence of
IFD is high locally. Although posaconazole prophylaxis
may potentially reduce these infections appreciably, a
significant minority (>35%) of IFD occur in hematology
patients where the data on the cost-effectiveness of
posaconazole prophylaxis is lacking. More needs to be
done to identify the patients and/or their risk factors in
order to deliver the appropriate antifungal prophylaxis.
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